Since its establishment in 2002, the Connecticut Cancer Partnership has grown from a core group of five organizations to a broad and diverse coalition more than 300 strong, representing elements of the cancer community from across Connecticut. Highlights of the Partnership’s history are given below.
Refusing Cancer Medications to Avoid Delirium and Maintain Autonomy By Kimberly Petrovic, PhD MSN MA RN, Assistant Professor of Nursing, SCSU Thomas O. Blank, Ph.D., Professor Emeritus, Human Development and Family Studies, UConn Shared decision-making within the patient-provider relationship is considered a cornerstone of the contemporary treatment of cancer here in Connecticut as well as nationally. It will be the focus of the 2017 Annual Meeting of the Connecticut Cancer Partnership. The relationship between patient and provider is critical and needs to develop and grow without diminishing the ultimate goals of cancer treatment: cure (whenever possible) and comfort (as…
This article was published in the January 2017, Volume 81, Number 1, issue of Connecticut Medicine and is reprinted here with permission.
Join The Jackson Laboratory for Genomic Medicine (JAX) for three upcoming educational events on the role of genomics in breast cancer. Through a generous grant from the Connecticut Breast Health Initiative Inc., these unique events will incorporate perspectives from breast cancer survivors, clinicians, and researchers to provide insight into current and future uses of genomics in breast cancer detection, diagnosis, treatment, and ongoing management. Beyond Genetics: genomics in breast cancer diagnosis, treatment and research Register here for the April 18, 2017 event – Early detection and diagnosis Register here for the May 2, 2017 event – Treatment and Precision…
Researchers at Yale Cancer Center have identified a new subtype of triple negative breast cancer that shows significantly improved response to chemotherapy. Patients with the newly defined subtype — BRCA-deficient triple negative breast cancer — had significantly higher survival rates with chemotherapy. The study was published on Dec. 13 in PLOS Medicine. Triple negative breast cancer (TNBC) disproportionately affects young women of all races and women of African ancestry, contributing to health disparities. In an era when personalized cancer therapy has improved survival rates, patients with TNBC remain at considerably higher risk of relapse and death than patients with other…
The CDC Public Health Genomics Knowledge Base is an online, continuously updated, searchable database of published scientific literature, CDC resources, and other materials that address the translation of genomic discoveries into improved health care and disease prevention. The Knowledge Base, cosponsored by the Division of Cancer Control and Population Sciences at the National Cancer Institute, is curated by CDC staff and is regularly updated to reflect ongoing developments in the field. This compendium of databases can be searched for genomics-related information on any specific topic. We will continue to add additional features to the knowledge base and are interested in…
Cancer and Health Policy–Post election Analysis and Implications, Matthew Katz, Connecticut State Medical Society, Chief Executive Officer
Read more here:
CLICK TO DOWNLOAD POWERPOINT PRESENTATION
Genomics Breakfast Meeting–Dec. 6, 2016-Evidence-based Public Health and Screening for Hereditary Cancer Syndromes